LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer


London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointment of a CSO with extensive clinical expertise comes at a pivotal time for LIfT, as the Company prepares for clinical trials of its first-in-class immuno-modulator, designed to rejuvenate patient immunity and overcome treatment resistance in solid tumours.

Go here to see the original:
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer

Related Posts